Evolent Health’s Q3 non-GAAP EPS beats analyst estimates by $0. 49!

Trending News 🌥️

Evolent Health ($NYSE:EVH) is a healthcare technology company that provides a platform for health systems and payers. The company’s Q3 non-GAAP EPS of $0. 49. Evolent Health’s platform enables health systems and payers to improve clinical and financial outcomes.

The company’s Q3 results show that its platform is delivering results for its customers. Evolent Health is committed to improving the healthcare system. The company’s Q3 results show that its platform is making a positive impact on the healthcare system.

Earnings

Total revenue increased 19.8% year-over-year, driven by growth in both its managed services and health plan businesses. Evolent Health‘s strong Q3 results continue a trend of strong growth for the company. This growth has been driven by both organic growth and acquisitions. Evolent Health’s Q3 results show that the company is continuing to execute on its growth strategy. With strong growth in both its core businesses, Evolent is well-positioned to continue delivering strong results in the quarters to come.

Stock Price

Evolent Health stock opened at $28.9 on Wednesday and closed at $28.5, down 1.6% from the prior closing price of 28.9. The majority of media coverage surrounding Evolent Health has been negative as of late. However, the company’s strong Q3 performance proves that it is still a force to be reckoned with. Only time will tell if Evolent Health can continue to outperform expectations in the face of adversity.

VI Analysis

Evolent Health is a healthcare technology company that partners with health systems and providers to drive clinical and financial results. The company’s platform enables its partners to better coordinate care, improve population health, and lower costs. Evolent Health’s platform is powered by data and analytics, and the company has a strong focus on customer success. The company’s platform is used by some of the largest healthcare organizations in the United States, including Ascension, Dignity Health, and Partners HealthCare.

Evolent Health is a high-risk investment in terms of financial and business aspects, according to VI Risk Rating. VI App has detected 3 risk warnings in income sheet, balance sheet, cashflow statement. Register on vi.app to check it out.

VI Peers

The company’s products and services enable healthcare providers to receive and process payments from patients and third-party payers. Evolent Health Inc’s competitors include PreAxia Health Care Payment Systems Inc, Livecare Inc, PT Bundamedik Tbk, and other healthcare payment processing companies.

– PreAxia Health Care Payment Systems Inc ($OTCPK:PAXH)

PreAxia Health Care Payment Systems Inc is a healthcare technology company that provides solutions to healthcare organizations and payers. Its products and services include claims processing, payment processing, and data management. The company was founded in 1997 and is headquartered in Boston, Massachusetts.

– Livecare Inc ($OTCPK:LVCE)

The companyPT Bundamedik Tbk is a leading healthcare provider in Indonesia. The company has a market cap of 4.73T as of 2022 and a ROE of 10.69%. The company is focused on providing quality healthcare services to the Indonesian people. The company has a strong presence in the Indonesian healthcare market and is committed to providing the best possible care to its patients.

Summary

Investing in Evolent Health could be a smart move, as the company is seeing strong growth and is expected to continue to perform well in the future. The company has a strong track record of delivering results, and its stock has been on a tear in recent years. Evolent Health is a healthcare services company that provides value-based care solutions to payers and providers.

The company has a strong focus on quality and cost-effective care, and has been able to drive impressive results for its clients. If you are looking for a healthcare services company that is delivering strong results and is expected to continue to do so in the future, Evolent Health could be a good option to consider.